Opportunities of using nadroparin calcium for prevention thrombotic complications at risk of coagulopathic bleeding-Reference-Cited by-同舟云学术

Opportunities of using nadroparin calcium for prevention thrombotic complications at risk of coagulopathic bleeding

Published:2024-01-04 Issue:6 Volume:17 Page:801-810
ISSN:2500-3194
Container-title:Obstetrics, Gynecology and Reproduction
language:
Short-container-title:Akušerstvo, ginekologiâ i reprodukciâ

Author:

Sushko T. A.¹^ORCID,Zainulina M. S.²^ORCID

Affiliation:

1. Snegirev Maternity Hospital № 6

2. Snegirev Maternity Hospital № 6; Pavlov First Saint Petersburg State Medical University, Health Ministry of Russian Federation

Abstract

An obstetrician-gynecologist faces in clinical practice cases requiring to weigh up not only benefits of administering preventive agents for venous thromboembolic complications (VTEC) but also risks related to concomitant coagulopathy. Here, we discuss issues related to using low molecular weight heparins (LMWHs) in pregnancy particularly nadroparin calcium for patients at high risk of VTEC and immune thrombocytopenia as a factor of coagulopathic bleedings.published VTEC prevention data in pregnancy and postpartum are presented. Moreover, literature review about VTEC prevention effect on pregnancy course and delivery in women with immune thrombocytopenia are discussed. A clinical case of a patient with immune thrombocytopenia and high thrombosis risk during pregnancy along with administered calcium nadroparin is described.

Publisher

IRBIS

Reference25 articles.

1. Rath W.H., Stelzl P. Strategies for the prevention of maternal death from venous thromboembolism clinical recommendations based on current literature. J Perinatal Med. 2023;51(2):213–8. https://doi.org/10.1515/jpm-2022-0069.

2. Rath W., Tsikouras P. Maternal deaths worldwide falling – but commonly preventable. Z Geburtshilfe Neonatol. 2018;222(4):143–51. (In German). https://doi.org/10.1055/a-0607-2816.

3. Croles F.N., Nasserinejad К., Duvekot J.J. et al. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis. BMJ. 2017;359:j4452. https://doi.org/10.1136/bmj.j4452.

4. Simioni P., Tormene D., Spiezia L. et al. Inherited thrombophilia and venous thromboembolism. Semin Thromb Hemost. 2006;32(7):700–8. https://doi.org/10.1055/s-2006-951298.

5. Abrahams V.M. Mechanisms of antiphospholipid antibody-associated pregnancy complications. Thromb Res. 2009;124(5):521–5. https://doi.org/10.1016/j.thromres.2009.07.011.